Collectively, these results corroborate our previous findings, facilitate a better molecular understanding of the role of CBFβ-MYH11 in the pathogenesis of leukemia, and might ultimately help to improve therapy decision of inv(16) AML by designing specific (epi)drugs to reprogram GATA2 or other target genes. Here, MYH11 is linked to leukemia.